Kiniksa Pharmaceuticals International, plc

KNSA

$78.00

Updated: 22/09/2026, 23:29:47

Market Cap

$5.94B

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

Stock valuation chart

One-year closing share-price history for KNSA

Company Profile

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

USD

NASDAQ

CEO: Sanj K. Patel

Employees: 366

https://www.kiniksa.com

Asset Summaries

Latest generated summaries for KNSA

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for KNSA.

Share price: $78.00
Market cap: $5.94B
Exchange: NASDAQ
Currency: USD
CEO: Sanj K. Patel
Employees: 366
IPO date: 24/05/2018
Beta: 0.08699999999999999
Last dividend: $0.00
Day range: $77.37 – $79.40
52-week range: $35.20 – $82.94
1-day performance: -0.17%
1-year performance: 121.59%
Current drawdown (1Y): -5.96%
CIK: 0001730430
CUSIP: N/A
ISIN: GB00BRXB0C07
Created: 07/12/2025, 04:58:12
Last update: 22/09/2026, 23:29:47

Track Kiniksa Pharmaceuticals International, plc with an AI analyst

See which prediction-market events move KNSA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to KNSA from your Railway `news_articles` table.

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

MarketBeat • STOCK • 14/08/2026, 23:02:35

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 10/06/2026, 03:22:09

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewsWire • STOCK • 29/05/2026, 18:01:00

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Seeking Alpha • STOCK • 29/04/2026, 13:10:24

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 28/04/2026, 19:21:38

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Zacks Investment Research • STOCK • 28/04/2026, 11:46:12

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

GlobeNewsWire • STOCK • 23/04/2026, 18:01:00

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

GlobeNewsWire • STOCK • 19/02/2026, 17:01:00

Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator

Seeking Alpha • STOCK • 24/01/2026, 01:40:49